MET and non-small cell lung carcinoma: On the basis of the findings, two phase II trials are ongoing with savolitinib in patients with EGFR mutant-NSCLC with MET amplification and progression on previous osimertinib (SAVANNAH (NCT03778229) and ORCHARD (NCT03944772) trials).